Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Alongside the development of an ever-increasing number of cancer therapies available for patients, cancer survivorship has steadily increased over the past three decades, and the impact on patients has been significant.1 However, with new therapies, comes new challenges, and the management of cancer therapy-related cardiovascular toxicity (CTR-CVT) has become an important consideration for healthcare professionals.2
Chronic Lymphocytic Leukemia (CLL)
Extended follow-up of the ALPINE trial: superior outcomes with zanubrutinib in R/R CLL/SLL
Jennifer Brown, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
Addressing cardiovascular AEs associated with BTKi treatment in patients with CLL
Lee Greenberger, PhD
Leukemia & Lymphoma Society, New York, NY
Long-term outcomes and toxicities of ibrutinib in CLL
Alessandra Ferrajoli, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Managing cumulative cardiovascular toxicity associated with BTK inhibitors
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA
Continuous BTK inhibitors in CLL treatment: benefits and drawbacks
Kerry Rogers, MD, The Ohio State University, Columbus, OH
Real-world incidence of ibrutinib-related cardiotoxicity in CLL
Lee Greenberger, PhD
Leukemia & Lymphoma Society, New York, NY
Lymphoma
Cardiovascular outcomes of patients with FL & DLBCL treated with doxorubicin-based chemotherapy
Vincent Camus, MD, University of Rouen, Rouen, France
Mitigating cardiological toxicities associated with BTKi in B-cell malignancies
Alessandra Ferrajoli, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma
Kim Linton, MBChB, MRCP, PhD, FRCP, The Christie NHS Foundation Trust, Manchester, UK
Amyloidosis
CHIP in patients with AL amyloidosis: clinical implications
Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA
The importance of the MDT to provide adequate treatment and care to patients with amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy
Acute Myeloid Leukemia (AML) & Myelodysplastic Syndromes (MDS)
Cardiotoxicity of CPX-351 vs 7+3 chemotherapy in AML
Jorge Cortes, MD, Augusta University, Augusta, GA
Clonal hematopoiesis in AML & insights into a novel CHIP risk stratification score
Benjamin Ebert, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
MCL-1 inhibition with AZD5991 in R/R hematologic malignancies
Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York City, NY
Leukemia
Improving care in adult patients with leukemia at high-risk of CV adverse events
Ahsan Ayaz, MD
Montefiore St. Luke’s Cornwall, Newburgh, NY
Exploring CV mortality risk in adult patients with leukemia
Ahsan Ayaz, MD
Montefiore St. Luke’s Cornwall, Newburgh, NY
Myeloproliferative neoplasms (MPNs)
Addressing the increased risk of cardiovascular disease in patients with MPNs
Arjun Ghosh, MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS
University College London Hospitals, London, UK
General hematological malignancies
Taking into account CV events as patients with hematological malignancies are treated long-term
Daniel Addison, MD
The Ohio State University Wexner Medical Center, Columbus, OH
Cardio-oncology: an emerging field within cancer treatment
Orly Leiva, MD, NYU Langone Health, New York City, NY
Common cardiovascular toxicities in patients with hematological malignancies
Daniel Addison, MD
The Ohio State University Wexner Medical Center, Columbus, OH
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon, MA, BM BCh, PhD, FRCP, FHFA
Royal Brompton Hospital, London, UK
The importance of cardio-oncology, awareness around the ESC 2022 cardio-oncology guidelines, and the value of building a multidisciplinary team
Daniel Lenihan, Raul Cordoba, and Iskra Pusic
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh, MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS
University College London Hospitals, London, UK
Sources
- Vaz-Luis I, et al. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol 2022;33:1119–33.
- Lyon A, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022;23:e333–e465.
Glossary
AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CTR-CVT, cancer-therapy cardiovascular-related toxicity; MDS, myelodysplastic syndromes.
This educational activity has received independent medical education support from Johnson & Johnson. This supporter has no influence over the production of the content.
